TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10816930
Drug: Referral guidelines
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral guidelines for orthodontic treatment
Study: 1351804
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tramadol hydrochloride
Study: 1351804
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tramadol hydrochloride
Study: 1351804
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus propoxyphene napsylate (650 mg + 100 mg)
Study: 2693683
Drug: 1% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metronidazole gel
Study: 24113254
Drug: 17-alpha hydroxyprogesterone
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha hydroxyprogesterone caproate 250 mg weekly
Study: 16236835
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg/d
Study: 10534607
Drug: Nalbuphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 5 mg, 10 mg, 20 mg
Study: 9695717
Drug: Disulfiram (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (500 mg oral)
Study: 9560064
Drug: Thioridazine 75
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine 75 mg (TDZ)
Study: 9560064
Drug: Thioridazine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (0, 25, 50 mg)
Study: 9560064
Drug: Thioridazine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (75 mg)
Study: 27720981
Drug: Alkalinised 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinised 0.75% ropivacaine-2% mepivacaine solution (pH 7.0)
Study: 27720981
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local anaesthetic solution (0.75% ropivacaine 5ml and 2% mepivacaine 5ml, pH 5.9)
Study: 26360446
Drug: REFOCUS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REFOCUS intervention (usual treatment plus REFOCUS)
Study: 26360446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual treatment alone)
Study: 17886373
Drug: Affinoleukin added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Affinoleukin added to regular treatment
Study: 17886373
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment alone
Study: 11206236
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 400 microg once daily in the morning (AM)
Study: 11206236
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg once daily in the evening (PM)
Study: 11206236
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg twice daily
Study: 786353
Drug: acebutolol (Sectral)
Normalized name: acebutolol Oral Capsule [Sectral]
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acebutolol (Sectral) 300 mg
Study: 786353
Drug: practolol (Eraldin)
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: practolol (Eraldin) 300 mg
Study: 31981921
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous co-amoxiclav
Study: 23370069
Drug: Coordinated Anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated Anxiety Learning and Management (CALM) collaborative care intervention (cognitive‐behavioral therapy and/or medication)
Study: 23370069
Drug: Opioid medications
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid medications in patients with comorbid major depression
Study: 23370069
Drug: Opioid medications
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid medications in patients with pain
Study: 21514147
Drug: docetaxel/oxaliplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel/oxaliplatin (75 mg/m² on day 1 and 70 mg/m² on day 2 every 3 weeks)
Study: 21514147
Drug: docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (75 mg/m² on day 1 every 3 weeks)
Study: 18451314
Drug: tNSAIDs, glucocorticoids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tNSAIDs, glucocorticoids, or coxibs (any inhibitor) with NT-proBNP > or = 100 ng/L
Study: 18451314
Drug: Coxibs (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coxibs (alone or with tNSAIDs or glucocorticoids) with NT-proBNP > or = 100 ng/L
Study: 18451314
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more antiinflammatory drugs with NT-proBNP > or = 100 ng/L
Study: 18451314
Drug: NT-proBNP <100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP <100 ng/L across all treatment groups
Study: 17040253
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in male patients
Study: 17040253
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in female patients
Study: 17040253
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in male patients (excluding COMPANION trial)
Study: 17040253
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in female patients (excluding COMPANION trial)
Study: 12943944
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants (clomipramine mean dose 145 mg and fluoxetine mean dose 27 mg)
Study: 12943944
Drug: Noradrenergic antidepressants
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic antidepressants (desipramine mean dose 200 mg and nortriptyline mean dose 100 mg)
Study: 12943944
Drug: Noradrenergic antidepressants
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic antidepressants
Study: 24971677
Drug: EX‐rST: combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX‐rST: combination of EX and rST
Study: 7661161
Drug: Triple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk
Study: 7661161
Drug: Omeprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk
Study: 7661161
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk
Study: 2596423
Drug: Daily alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily alternating slimming diet
Study: 23656173
Drug: Cerebrolysin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60‐min period for 5 days)
Study: 23656173
Drug: Placebo (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Group B, same dosage and administration of normal saline as Group A)
Study: 22248833
Drug: H5N1-AS03(A) adjuvanted
Normalized name: Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 [AS03 Adjuvant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1-AS03(A) adjuvanted formulations
Study: 22248833
Drug: H5N1-DIL nonadjuvanted
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1-DIL nonadjuvanted formulations
Study: 19193660
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (1.6 g/meal) rich in n‐3 alpha‐linolenic acid (ALA)
Study: 19193660
Drug: Commercial complementary
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial complementary meals with corn oil (3.4 g/meal) rich in n‐6 linoleic acid (LA)
Study: 10591382
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg of intra-arterial recombinant prourokinase (r-proUK) plus heparin
Study: 10591382
Drug: Heparin only
Normalized name: Heparin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin only (control)
Study: 8708717
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin (FA) 500 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group A)
Study: 8708717
Drug: Low-dose leucovorin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leucovorin (FA) 20 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group B)
Study: 1788750
Drug: Intravenous PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGE1 (60 mcg)
Study: 6267643
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of naloxone IV
Study: 6267643
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of naloxone
Study: 30280459
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg selenium/day as selenium-enriched yeast
Study: 30280459
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium/day as selenium-enriched yeast
Study: 30280459
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg selenium/day as selenium-enriched yeast
Study: 27545511
Drug: Ibuprofen IR/ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen IR/ER 600 mg (formulation A)
Study: 27545511
Drug: Ibuprofen IR/ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen IR/ER 600 mg (formulation B)
Study: 15545544
Drug: 5 U
Normalized name: vitamin E 5 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 U of botulinum exotoxin A in 0.25 mL of preserved saline (2 U/0.1 mL)
Study: 15545544
Drug: 5 U
Normalized name: vitamin E 5 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 U of botulinum exotoxin A in 0.05 mL of preserved saline (2 U/0.02 mL)
Study: 11319508
Drug: Estriol treatment
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol treatment per vaginam
Study: 11319508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no estriol treatment)
Study: 8043059
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy plus surgery
Study: 3306494
Drug: labetalol (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (20‐80 mg)
Study: 3306494
Drug: hydralazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydralazine (5 mg)
Study: 22087680
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (2 g per day)
Study: 12162602
Drug: Individualized calcium
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized calcium (Ca) and phosphorus (P) supplementation adjusted to achieve urinary excretion of > or = 1.2 mmol/L Ca and > or = 0.4 mmol/L P.
Study: 7644079
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 25 mg
Study: 7640145
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 50 mg
Study: 7768259
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan
Study: 2787310
Drug: Lung hyperinflation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung hyperinflation at tidal volume 12 cc/kg
Study: 2787310
Drug: Lung hyperinflation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung hyperinflation at tidal volume 14 cc/kg
Study: 2787310
Drug: Lung hyperinflation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung hyperinflation at tidal volume 16 cc/kg
Study: 2787310
Drug: Lung hyperinflation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung hyperinflation at tidal volume 18 cc/kg
Study: 342359
Drug: Carbenoxolone capsules
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone capsules (Duogastrone, 50 mg four times a day for six weeks)
Study: 342359
Drug: Carbenoxolone capsules
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone capsules
Study: 31866104
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy for drug abusers (120 days treatment)
Study: 31866104
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy for alcohol abusers (90 days treatment)
Study: 31866104
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy for both groups
Study: 28646811
Drug: Tui na
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tui na treatment (2 times/week for 10 weeks, 15 min/session)
Study: 28646811
Drug: Tui na
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tui na treatment
Study: 26110296
Drug: co‐trimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (960 mg twice a day)
Study: 26110296
Drug: norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin (400 mg twice a day)
Study: 26110296
Drug: levofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin (250 mg once a day)
Study: 17114880
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose in addition to standard acetylsalicylic acid/heparin treatment
Study: 15119913
Drug: Supportive clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive clinical environment treatment program
Study: 29958049
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oral NAC
Study: 16914594
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human TSH (rhTSH) preparation
Study: 16914594
Drug: hypothyroid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypothyroid preparation
Study: 15273269
Drug: Asthma screening
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma screening questionnaire administered to parents
Study: 11093918
Drug: H(2)-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(2)-receptor antagonists (cimetidine or ranitidine)
Study: 11093918
Drug: H(1)-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(1)-receptor antagonist (mepyramine)
Study: 11093918
Drug: H(1)- and
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H(1)- and H(2)-receptor blockade
Study: 8471592
Drug: Interferon-gamma at
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma at 0.1 mg/m2
Study: 8471592
Drug: Interferon-gamma at
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma at 0.25 mg/m2
Study: 8471592
Drug: Interferon-gamma at
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma at 0.01 mg/m2
Study: 3519353
Drug: Methylergometrin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylergometrin (0.125 mg, 3 times a day for 4 weeks)
Study: 3042354
Drug: urapidil 60
Normalized name: urapidil 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 60 mg twice daily (adjustable to 30 mg, 60 mg, or 90 mg based on blood pressure response)
Study: 3042354
Drug: captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 25 mg twice daily (adjustable to 12.5 mg, 25 mg, or 50 mg based on blood pressure response)
Study: 25553110
Drug: PEG-IFN therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN therapy
Study: 16584354
Drug: Antibiotics (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Study: 30869644
Drug: App-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based treatment program (Tät app) for SUI, 3-month duration focusing on pelvic floor muscle training (PFMT)
Study: 30869644
Drug: App-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based treatment program (Tät app) for SUI
Study: 29574600
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with near complete or complete recanalization (TICI grades 2b and 3)
Study: 25486269
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication (various types)
Study: 9496247
Drug: Subcutaneous glucagon-like
Normalized name: Glucagon-like peptide II (2-glycine) (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) at a dosage of 0.5 nmol/kg
Study: 9496247
Drug: Subcutaneous glucagon-like
Normalized name: Glucagon-like peptide II (2-glycine) (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1)
Study: 2917311
Drug: Tamoxifen in
Normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen in combination with standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Study: 2917311
Drug: Standard cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Study: 2917311
Drug: Cytosol steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytosol steroid receptor determinations
Study: 27053235
Drug: 6.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/kg ATG (Thymoglobulin)
Study: 24713613
Drug: Sulpiride (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (high dose selective DA D2/3-receptor antagonist)
Study: 23279492
Drug: Betamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (0.5 mg/kg) administered at 55 days post-ovulation
Study: 23279492
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution administered at 55 days post-ovulation (Control Group)
Study: 19852302
Drug: Runmushu Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runmushu Oral Liquid (RMS) combined with Hialid eye drops
Study: 17252006
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation with subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks
Study: 17252006
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks without intravenous iron
Study: 17252006
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation with subcutaneous epoetin beta
Study: 11235144
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist with flutamide (n = 5)
Study: 11235144
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist mono-therapy (n = 4)
Study: 9648044
Drug: Stimulant use
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant use as prescribed (Ritalin)
Study: 9648044
Drug: Stimulant use
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant use (Ritalin)
Study: 9648044
Drug: Stimulant storage
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant storage policies in schools
Study: 9648044
Drug: School policies
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School policies regarding prescription drugs
Study: 9648044
Drug: School policies
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School policies regarding medication carrying
Study: 31928949
Drug: Subanesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic ketamine (0.5 mg/kg)
Study: 29450737
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral hygiene intervals (12 and 24 hours)
Study: 29450737
Drug: Extended oral
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended oral hygiene intervals (48 and 72 hours)
Study: 28194525
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35 mg TID
Study: 28194525
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35 mg BID
Study: 28194525
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35 mg TID and BID
Study: 15522553
Drug: docetaxel‐based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel‐based chemotherapy - six cycles (DXL-epirubicin: 13 patients, DXL alone: 15 patients)
Study: 11553189
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg b.i.d. for 6 months